AEON Biopharma, Inc. Announces Launch of Proposed Public Offering
AEON Biopharma (NYSE: AEON) has announced the launch of a proposed public offering of units comprising common stock (or pre-funded warrants) and warrants to purchase common stock. The clinical-stage biopharmaceutical company, focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, has appointed Aegis Capital Corp. as the sole book-running manager on a firm commitment basis.
The offering includes a 45-day option for Aegis Capital Corp. to purchase additional shares up to 15% of total shares sold to cover over-allotments. AEON plans to use the net proceeds for general corporate and working capital needs. The offering is being conducted through an effective shelf registration statement on Form S-3 and is subject to market conditions, with no guarantee of completion or final terms.
AEON Biopharma (NYSE: AEON) ha annunciato il lancio di un'offerta pubblica proposta di unit脿 composte da azioni ordinarie (o warrant pre-finanziati) e warrant per l'acquisto di azioni ordinarie. L'azienda biopharmaceutica in fase clinica, focalizzata sullo sviluppo di un complesso tossico botulinico secondo un percorso biosimilare 351(k), ha nominato Aegis Capital Corp. come unico gestore dell'offerta su base di impegno fermo.
L'offerta include un'opzione di 45 giorni per Aegis Capital Corp. di acquistare ulteriori azioni fino al 15% del totale delle azioni vendute per coprire sovrallocamenti. AEON prevede di utilizzare i proventi netti per esigenze generali aziendali e di capitale circolante. L'offerta viene condotta attraverso una dichiarazione di registrazione a scaffale efficace sul modulo S-3 ed 猫 soggetta alle condizioni di mercato, senza garanzia di conclusione o termini finali.
AEON Biopharma (NYSE: AEON) ha anunciado el lanzamiento de una oferta p煤blica propuesta de unidades que comprenden acciones ordinarias (o warrants prefinanciados) y warrants para comprar acciones ordinarias. La compa帽铆a biofarmac茅utica en etapa cl铆nica, centrada en desarrollar un complejo de toxina botul铆nica bajo una v铆a biosimilar 351(k), ha designado a Aegis Capital Corp. como el 煤nico gerente de libro de la oferta con un compromiso firme.
La oferta incluye una opci贸n de 45 d铆as para que Aegis Capital Corp. adquiera acciones adicionales hasta el 15% del total de acciones vendidas para cubrir sobreasignaciones. AEON planea utilizar los ingresos netos para necesidades corporativas generales y de capital de trabajo. La oferta se lleva a cabo a trav茅s de una declaraci贸n de registro de estante efectiva en el formulario S-3 y est谩 sujeta a condiciones de mercado, sin garant铆a de finalizaci贸n o t茅rminos finales.
AEON Biopharma (NYSE: AEON)鞚� 氤错喌欤� (霕愲姅 靷爠 鞛愱笀 歆�鞗愲悳 鞗岆煱韸�)鞕� 氤错喌欤� 甑Г毳� 鞙勴暅 鞗岆煱韸鸽 甑劚霅� 鞙犽嫑鞚� 瓿惦 鞝滌晥鞚� 氚滍憸頄堨姷雼堧嫟. 鞛勳儊 雼硠鞚� 靸濍鞝滌暯 須岇偓搿滌劀, 351(k) 氚旍澊鞓れ嫓氚�霟� 瓴诫鞐� 霐半澕 氤错埓毽垟 霃呾唽 氤淀暕觳措ゼ 臧滊皽頃橂姅 雿� 欷戩爯鞚� 霊愱碃 鞛堨溂氅�, Aegis Capital Corp.毳� 雼弲 攵� 旎る矂毽 毵る媹鞝�搿� 鞛勲獏頄堨姷雼堧嫟.
鞚措矆 瓿惦鞐愲姅 Aegis Capital Corp.臧� 韺愲Г霅� 齑� 欤检嫕鞚� 斓滊寑 15%旯岇 於旉皜 欤检嫕鞚� 甑Г頃� 靾� 鞛堧姅 45鞚缄皠鞚� 鞓奠厴鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. AEON鞚� 靾滌垬鞚奠潉 鞚茧皹 旮办梾 鞖挫榿 氚� 鞖挫爠 鞛愲掣 頃勳殧鞐� 靷毄頃� 瓿勴殟鞛呺媹雼�. 鞚措矆 瓿惦電� 須牓 鞛堧姅 靹犽皹 霌彪 靹彪獏靹滊ゼ 韱淀暣 歆勴枆霅橂┌, 鞁滌灔 靸來櫓鞐� 霐半澕 雼るゴ氅�, 鞕勲 霕愲姅 斓滌 臁瓣贝鞐� 雽�頃� 氤挫灔鞚� 鞐嗢姷雼堧嫟.
AEON Biopharma (NYSE: AEON) a annonc茅 le lancement d'une offre publique propos茅e d'unit茅s comprenant des actions ordinaires (ou des bons pr茅financ茅s) et des bons d'achat d'actions ordinaires. Cette entreprise biopharmaceutique en phase clinique, ax茅e sur le d茅veloppement d'un complexe de toxines botuliques selon une voie biosimilaire 351(k), a nomm茅 Aegis Capital Corp. en tant que seul gestionnaire de livre sur une base d'engagement ferme.
L'offre inclut une option de 45 jours pour Aegis Capital Corp. d'acheter des actions suppl茅mentaires jusqu'脿 15 % du total des actions vendues pour couvrir les surallocations. AEON pr茅voit d'utiliser les produits nets pour ses besoins en fonds de roulement et pour ses besoins d'exploitation g茅n茅rale. L'offre est r茅alis茅e par le biais d'une d茅claration d'enregistrement de type 茅tag猫re efficace sur le formulaire S-3 et est soumise aux conditions du march茅, sans garantie de r茅alisation ou de conditions finales.
AEON Biopharma (NYSE: AEON) hat die Einf眉hrung eines vorgeschlagenen 枚ffentlichen Angebots von Einheiten bekannt gegeben, die aus Stammaktien (oder vorfinanzierten Warrants) und Warrants zum Kauf von Stammaktien bestehen. Das klinische Biopharmazeutikunternehmen, das sich auf die Entwicklung eines Botulinumtoxin-Komplexes im Rahmen eines 351(k) Biosimilar-Pfads konzentriert, hat Aegis Capital Corp. als einzigen Book-Running-Manager auf fester Verpflichtungsbasis bestellt.
Das Angebot enth盲lt eine 45-t盲gige Option f眉r Aegis Capital Corp., zus盲tzliche Aktien bis zu 15 % der insgesamt verkauften Aktien zu erwerben, um 脺berzuteilungen zu decken. AEON plant, die Nettoerl枚se f眉r allgemeine Unternehmens- und Betriebskapitalbed眉rfnisse zu verwenden. Das Angebot wird 眉ber eine wirksame Shelf-Registrierungserkl盲rung auf Formular S-3 durchgef眉hrt und unterliegt den Marktbedingungen, ohne Garantie f眉r den Abschluss oder die endg眉ltigen Bedingungen.
- Secured firm commitment from Aegis Capital Corp. as book-running manager
- Effective shelf registration statement already in place
- Additional working capital to support operations
- Potential dilution for existing shareholders
- Uncertain offering terms and completion timeline
- Market-dependent pricing conditions
Insights
IRVINE, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (鈥淎EON鈥� or the 鈥淐ompany鈥�) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced that it has commenced a public offering (the 鈥淥ffering鈥�) to offer and sell units, consisting of (i) shares of Common Stock (or pre-funded warrants in lieu thereof) and (ii) warrants to purchase shares of Common Stock.
In addition, the Company expects to grant Aegis Capital Corp. a 45-day option to purchase additional shares of Common Stock representing up to
The Company intends to use the net proceeds from the Offering for general corporate and working capital needs.
The Company鈥檚 Common Stock is trading on NYSE American under the symbol 鈥淎EON鈥�. The Offering is subject to market conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.
Aegis Capital Corp. is acting as the sole book-running manager for the Offering on a firm commitment basis. Sichenzia Ross Ference Carmel LLP is acting as counsel to the Company. Kaufman & Canoles, P.C. is acting as counsel to Aegis Capital Corp.
The Offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-281562) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on August 21, 2024. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC鈥檚 website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010. Before investing in this Offering, interested parties should read in their entirety the registration statement and the preliminary prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such registration statement and the preliminary prospectus, which provide more information about the Company and the Offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About AEON Biopharma
AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit .
Forward-Looking Statements
The foregoing material may contain 鈥渇orward-looking statements鈥� within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company鈥檚 product development and business prospects, and can be identified by the use of words such as 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渆xpect,鈥� 鈥減roject,鈥� 鈥渆stimate,鈥� 鈥渁nticipate,鈥� 鈥減lan,鈥� 鈥渂elieve,鈥� 鈥減otential,鈥� 鈥渟hould,鈥� 鈥渃ontinue鈥� or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the outcome of any legal proceedings that may be instituted against AEON or others; (ii) AEON鈥檚 future capital requirements; (iii) AEON鈥檚 ability to raise financing in the future; (iv) AEON鈥檚 ability to continue to meet continued stock exchange listing standards; (v) the possibility that AEON may be adversely affected by other economic, business, regulatory, and/or competitive factors; and (vi) other risks and uncertainties set forth in the section entitled 鈥淩isk Factors鈥� and 鈥淐autionary Note Regarding Forward-Looking Statements鈥� in the Company鈥檚 filings with the Securities and Exchange Commission (the "SEC"), which are available on the SEC鈥檚 website at .
Contacts
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
Source: AEON Biopharma
FAQ
What type of securities is AEON Biopharma offering in its January 2024 public offering?
How will AEON Biopharma use the proceeds from its 2024 public offering?
Who is the book-running manager for AEON's 2024 public offering?
What is the over-allotment option in AEON's 2024 public offering?
Under which SEC registration is AEON conducting its 2024 public offering?
